Impact of dopamine and cognitive impairment on neural reactivity to facial emotion in Parkinson's disease.
Aged
Aged, 80 and over
Case-Control Studies
Cognitive Dysfunction
/ complications
Dopamine Agonists
/ pharmacology
Emotions
/ drug effects
Facial Expression
Female
Functional Neuroimaging
Humans
Magnetic Resonance Imaging
Male
Middle Aged
Neuroimaging
Neuropsychological Tests
Parkinson Disease
/ complications
Visual Cortex
/ drug effects
Cognitive function
Dopamine
Emotion
Facial recognition
Parkinson's disease
fMRI
Journal
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology
ISSN: 1873-7862
Titre abrégé: Eur Neuropsychopharmacol
Pays: Netherlands
ID NLM: 9111390
Informations de publication
Date de publication:
11 2019
11 2019
Historique:
received:
22
01
2019
revised:
04
09
2019
accepted:
11
09
2019
pubmed:
15
10
2019
medline:
8
9
2020
entrez:
15
10
2019
Statut:
ppublish
Résumé
Emotional and cognitive impairments in Parkinson's disease (PD) are prevalent, hamper interpersonal relations and reduce quality of life. It is however unclear to what extent these domains interplay in PD-related deficits and how they are influenced by dopaminergic availability. This study examined the effect of cognitive impairment and dopaminergic medication on neural and behavioral mechanisms of facial emotion recognition in PD patients. PD patients on and off dopaminergic medication and matched healthy controls underwent an emotional face matching task during functional MRI. In addition, a comprehensive neuropsychological evaluation of cognitive function was conducted. Increased BOLD response to emotional faces was found in the visual cortex of PD patients relative to controls irrespective of cognitive function and medication status. Administration of dopaminergic medication in PD patients resulted in restored behavioral accuracy for emotional faces relative to controls and decreased retrosplenial cortex BOLD response to emotion relative to off-medication state. Furthermore, cognitive impairment in PD patients was associated with reduced behavioral accuracy for non-emotional stimuli and predicted BOLD response to emotion in the anterior and posterior cingulate cortices, depending on medication status. Findings of aberrant visual and retrosplenial BOLD response to emotion are suggested to stem from altered attentional and/or emotion-driven modulation from subcortical and higher cortical regions. Our results indicate neural disruptions and behavioral deficits in emotion processing in PD patients that are dependent on dopaminergic availability and independent of cognitive function. Our findings highlight the importance of dopaminergic treatment not only for the motor symptoms but also the emotional disturbances in PD.
Identifiants
pubmed: 31607424
pii: S0924-977X(19)30877-6
doi: 10.1016/j.euroneuro.2019.09.003
pii:
doi:
Substances chimiques
Dopamine Agonists
0
Types de publication
Controlled Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1258-1272Informations de copyright
Copyright © 2019 Elsevier B.V. and ECNP. All rights reserved.